Skip to main content

Advertisement

SpringerLink
Log in

Idiopathic Aplastic anemia: Indian Perspective

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Aplastic anemia (AA) is a rare immunologically mediated bone marrow failure syndrome, characterized by progressive loss of hematopoietic stem cells resulting in peripheral pancytopenia. Elaborative investigation including molecular tests is required to exclude inherited bone marrow failure syndrome (IMBFS) as the treatment and prognosis vary dramatically between them. Haematopoietic stem cell transplant with a fully matched sibling donor (MSD-HSCT) is still the only curative treatment. Management of AA is a real-time challenge in India, because of the delay in the diagnosis, lack of proper supportive care, limited availability of the expertise centre, and the patient’s affordability. Recently, results with intensified immunosuppressive therapy that includes anti-thymocyte globulin with cyclosporine-A (CsA) and eltrombopag, are enough encouraging to consider it as treatment of choice in patients lacking MSD or who are not fit for HSCT. However, limitations in resource constraints settings including the cost of therapy limit its full utilization. Relapse of the disease or evolution to myelodysplasia or paroxysmal nocturnal haemoglobinuria (PNH) in a proportion of patients is another challenge with immunosuppressants. The majority of the AA patients still receive CsA with or without androgens in India, mostly because of increased cost and limited availability of HSCT and ATG. The use of the unrelated or alternative donor is still upcoming in India, with unavailable data in terms of response and survival. Therefore, there is an utmost need for novel agents for the better management of AA having a balanced efficacy and toxicity profile to improve the survival and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2a
Fig. 2b
Fig. 3

Similar content being viewed by others

Data Availability

Not applicable.

References

  1. Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:2509–2519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Maluf E, Hamerschlak N, Cavalcanti AB et al (2009) Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica 94:1220–1226

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vaht K, Göransson M, Carlson K et al (2017) Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica 102:1683–1690

    Article  PubMed  PubMed Central  Google Scholar 

  4. Issaragrisil S, Kaufman DW, Anderson T et al (2006) The epidemiology of aplastic anemia in Thailand. Blood 107:1299–1307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yong AS, Goh AS, Rahman M et al (1998) Epidemiology of aplastic anaemia in the state of Sabah, Malaysia. Med J Malaysia 53:59–62

    CAS  PubMed  Google Scholar 

  6. Jeong DC, Chung NG, Kang HJ et al (2011) Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years: retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO). J Pediatr Hematol Oncol 33:172–178

    Article  PubMed  Google Scholar 

  7. Kojima S (2017) Why is the incidence of aplastic anemia higher in Asia? Expert Rev Hematol 10:277–279

    Article  CAS  PubMed  Google Scholar 

  8. Kumar R, Kalra SP, Kumar H, Anand AC, Madan H (2001) Pancytopenia—a six year study. J Assoc Physicians India 49:1078–1081

    CAS  PubMed  Google Scholar 

  9. Mahapatra M, Singh PK, Agarwal M et al (2015) Epidemiology, clinicohematological profile and management of aplastic anemia:AIIMS Experience. J Assoc Physicians India 63:30–35

    CAS  PubMed  Google Scholar 

  10. Ahamed M, Anand M, Kumar A et al (2006) Childhood aplastic anaemia in Lucknow, India: incidence, organochlorines in the blood and review of case reports following exposure to pesticides. Clin Biochem 39:762–766

    Article  CAS  PubMed  Google Scholar 

  11. Goswami BK, Chakrabarti S, Paul PC, Pramanik R, Raha K, Das S (2009) Clinicohaematological analysis of aplastic anaemia among children of northern districts of West Bengal. J Indian Med Assoc 107:17–18

    PubMed  Google Scholar 

  12. Nair V, Sharma A, Das S, Sondhi V et al (2013) Immunosuppressive therapy in adults with aplastic anaemia: single-institution experience from India. Postgrad Med J 89:508–515

    Article  CAS  PubMed  Google Scholar 

  13. Dutta A, De R, Dolai T, Mitra P, Halder A (2019) Journal of Blood Disorders, Symptoms & Treatments. Comparative Study of Environmental Factors and Different Addictions in Aplastic Anaemia. Patients in Eastern India 2:1–8

    Google Scholar 

  14. Jain D, Kumar R, Tyagi N, Negi A, Pande A, Mahajan A, Pandey PK, Malik R, Raina V, Malik BK (2012 Nov) Etiology and survival of aplastic anemia: a study based on clinical investigation. J Clin Lab Anal 26(6):452–458. doi: https://doi.org/10.1002/jcla.21546 PMID: 23143628; PMCID: PMC6807622

  15. Young NS, Kaufman DW (2008) The epidemiology of acquired aplastic anemia. Haematologica 93:489–492

    Article  PubMed  Google Scholar 

  16. Kapoor M, Agrawal D, Ravi S et al (2019) Missing female patients: an observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India. BMJ Open 9:e026850

    Article  PubMed  PubMed Central  Google Scholar 

  17. Luzzatto L, Risitano AM (2018) Advances in understanding the pathogenesis of acquired aplastic anaemia. Br J Haematol 182:758–777

    Article  PubMed  Google Scholar 

  18. Scheinberg P, Young NS (2012) How I treat acquired aplastic anaemia. Blood 120:1185–1196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lin FC, Karwan M, Saleh B et al (2014) IFN-γ causes aplastic anemia by altering hematopoiesis stem/progenitor cell composition and disrupting lineage differentiation. Blood 124:3699–3708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Alvarado L, Huntsman HD, Cheng H, Knutson JR, Larochelle A (2017) Heterodimerization of TPO and IFNγ impairs human hematopoietic stem/progenitor cell signaling and survival in chronic inflammation. Blood 130:4

    Google Scholar 

  21. Townsley DM, Scheinberg P, Winkler T et al (2017) Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 376:1540–1550

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) The British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172:187–207

    Article  PubMed  Google Scholar 

  23. Rovo A, Tichelli A, Dufour C, Saa-Wp E (2013) Diagnosis of acquired aplastic anaemia. Bone Marrow Transplant 48:162–167

    Article  CAS  PubMed  Google Scholar 

  24. Locasciulli A, Oneto R, Bacigalupo A et al (2007) Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica 92:11–18

    Article  CAS  PubMed  Google Scholar 

  25. Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H (2013) Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 48:168–173

    Article  CAS  PubMed  Google Scholar 

  26. Foukaneli T, Kerr P, Bolton-Maggs PH, Cardigan R, Coles A, Gennery A, Jane D, Kumararatne D, Manson A, New HV, Torpey N and (2020) Guidelines on the use of irradiated blood components. Br J Haematol 191:704–724

    Article  PubMed  Google Scholar 

  27. Malhotra P, John JM (2015) Supportive Care and Newer Therapies in Aplastic Anaemia. J Assoc Physicians India 63(3 Suppl):26–29

    PubMed  Google Scholar 

  28. Valdez JM, Scheinberg P, Nunez O, Wu OC, Young NS, Walsh TJ (2011) Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades. Clin Infect Dis 52:726–735

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC (2009) Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 114:2315–2322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Bhatia V, Raghuwanshi B, Sahoo J (2016) Current status of blood banks in India. Glob J Transfus Med 1:72–74

    Article  Google Scholar 

  32. Estcourt LJ, Desborough M, Brunskill SJ, Doree C, Hopewell S, Murphy MF et al (2016) Antifibrinolytic (lysine analogues) for the prevention of bleeding in people with haematological disorders.Cochrane Database Syst Rev:CD009733

  33. Scheinberg P, Nunez O, Weinstein B et al (2011) Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365(5):430–438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A et al (2007) Treatment of severe aplastic anemia with antithymocyteglobulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 110:1756–1761

    Article  CAS  PubMed  Google Scholar 

  35. Bacigalupo A, Bruno B, Saracco P et al (2000) Antilymphocyteglobulin, cyclosporine, prednisolone, and granulocyte colony stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients: European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 95:1931–1934

    Article  CAS  PubMed  Google Scholar 

  36. Hayakawa J, Kanda J, Akahoshi Y et al (2017) Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol 105:578

    Article  CAS  PubMed  Google Scholar 

  37. Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM et al (2009) Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94:348–354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rosenfeld SJ, Kimball J, Vining D, Young NS (1995) Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 85:3058–3065

    Article  CAS  PubMed  Google Scholar 

  39. Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289:1130–1135

    Article  CAS  PubMed  Google Scholar 

  40. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101:1236–1242

    Article  CAS  PubMed  Google Scholar 

  41. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S et al (1999) Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 93:2191–2195

    Article  CAS  PubMed  Google Scholar 

  42. Dufour C, Pillon M, Socie G, Rovo A, Carraro E, Bacigalupo A et al (2015) Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol 169:565–573

    Article  PubMed  Google Scholar 

  43. Gill H, Leung GM, Lopes D, Kwong YL (2017) The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol 176:991

    Article  CAS  PubMed  Google Scholar 

  44. Lengline E, Drenou B, Peterlin P et al (2018) Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica 103:212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ramzan M, Yadav SP, Zafar MSH, Dinand V, Sachdeva A (2014) Outcome of pediatric acquired aplastic anemia: a developing world experience. Pediatr Hematol Oncol 31:29–38

    Article  PubMed  Google Scholar 

  46. Gupta V, Kumar A, Tilak V, Saini I, Bhatia B (2012) Immunosuppressive therapy in aplastic anemia. Indian J Pediatr 79:1587–1591

    Article  PubMed  Google Scholar 

  47. Agarwal MB, Jijina F, Shah S, Malhotra P, Damodar S, Ross C (2015) Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia. Indian J Hematol Blood Transfus 31:174–179

    Article  CAS  PubMed  Google Scholar 

  48. Shah S, Jain P, Shah K, Patel K, Parikh S, Patel A et al (2019) Immunosuppressive therapy for aplastic anemia: a single-center experience from western India. Ann Hematol 98:41–46

    Article  PubMed  Google Scholar 

  49. Amalnath DS (2020) Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India. Indian J Hematol Blood Transfus 36:473–476

    Article  PubMed  Google Scholar 

  50. Dutta B, Dolai TK, Mandal PK et al (2019) Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India. Indian J Hematol Blood Transfus. https://doi.org/10.1007/s12288-019-01158-x

    Article  PubMed  PubMed Central  Google Scholar 

  51. George B, Mathews V, Viswabandya A, Abraham A, Ganapule A, Fouzia NA et al (2015) Immunosuppressive therapy and bone marrow transplantation for aplastic anaemia—the CMC experience. J Assoc Physicians India 63:36–40

    PubMed  Google Scholar 

  52. Nair V, Sondhi V, Sharma A, Das S, Sharma S (2012) Survival after immunosuppressive therapy in children with aplastic anemia. Indian Pediatr 49:371–376

    Article  PubMed  Google Scholar 

  53. Malhotra P, Bodh V, Guru Murthy GS, Datta AK, Varma N, Varma S (2015) Outcomes of immunosuppressant therapy with lower dose of antithymocyte globulin and cyclosporine in aplastic anemia. Hematology 20:239–244

    Article  CAS  PubMed  Google Scholar 

  54. Patel AB, Panchal HP, Anand AS, Patel AA, Parikh SP, Shah SA (2015) Acquired severe aplastic anemia treated with antithymocyte globulin and cyclosporine: An experience of regional cancer center, Western India. J Appl Hematol 6:53–57

    Article  Google Scholar 

  55. Sharma R, Chandra J, Sharma S, Pemde H, Singh V (2012) Antithymocyte globulin and cyclosporine in children with aplastic anemia: a developing country experience. J Pediatr Hematol Oncol 34:93–95

    Article  CAS  PubMed  Google Scholar 

  56. Jain R, Trehan A, Bansal D, Varma N (2019) Aplastic anemia in children: How good is immunosuppressive therapy? Pediatr Hematol Oncol 36:211–221

    Article  PubMed  Google Scholar 

  57. Chandra J, Naithani R, Ravi R, Singh V, Narayan S, Sharma S et al (2008) Antithymocyte globulin and cyclosporin in children with acquired aplastic anemia. Indian J Pediatr 75:229–233

    Article  PubMed  Google Scholar 

  58. Narita A, Kojima S (2016) Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. Int J Hematol 104:153–158

    Article  CAS  PubMed  Google Scholar 

  59. Scheinberg P, Rios O, Scheinberg P et al (2014) Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol 89:571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Maciejewski JP, Selleri C (2004) Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma 45:433–440

    Article  PubMed  Google Scholar 

  61. Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129:1428–1436

    Article  CAS  PubMed  Google Scholar 

  62. Nair V, Apte S (2015) Stem cell transplantation in aplastic anemia.JAPI63. https://www.japi.org/u2c4b474/stem-cell-transplantation-in-aplastic-anaemia#.X14yAaRHTGE.link

  63. Bacigalupo A, Soci´e G, Schrezenmeier H et al (2012) Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 97:1142–1148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Peinemann F, Grouven U, Kröger N et al (2011) First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS ONE 6:e18572

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Peinemann F, Bartel C, Grouven U (2013) First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.Cochrane Database Syst Rev;:CD006407

  66. Bacigalupo A, Socié G, Schrezenmeier H et al (2012) Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 97:1142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. George B, Mathews V, Lakshmi KM et al (2013) Fludarabine based conditioning is associated with improved long term survival in patients with severe aplastic anemia a retrospective analysis from 3 Indian centers. Clin Transplant 6:923–929

    Article  Google Scholar 

  68. Nair V, Sharma A, Das S et al (2013) Allogeneic haematopoietic stem cell transplantation: The Army hospital experience. Natl Med J India 26:6–11

    CAS  PubMed  Google Scholar 

  69. Passweg JR, Socié G, Hinterberger W et al (1997) Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 90:85–88

    Google Scholar 

  70. Arai Y, Kondo T, Yamazaki H et al (2016) Japan Society for Hematopoietic Cell Transplantation. Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica 101:644–652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Storb R, Etzioni R, Anasetti C et al (1994) Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84(3):941–949

    Article  CAS  PubMed  Google Scholar 

  72. Aljurf M, Al-Zahrani H, Van Lint MT, Passweg JR (2013) Standard treatment of acquired SAA in adult patients 18–40 years old with an HLA-identical sibling donor. Bone Marrow Transplant 48:178–179

    Article  CAS  PubMed  Google Scholar 

  73. Chandy M, Srivastava A, Dennison D, Mathews V, George B (2001) Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 27:785–790

    Article  CAS  PubMed  Google Scholar 

  74. Kumar R, Prem S, Mahapatra M, Seth T, Chowdhary DR, Mishra P et al (2006) Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant 37:745–749

    Article  CAS  PubMed  Google Scholar 

  75. George B, Mathews V, Viswabandya A et al (2007) Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant 40:13–18

    Article  CAS  PubMed  Google Scholar 

  76. Chandy V (2008) Stem cell transplantation in India. Bone Marrow Transplant 42:S81–84

    Article  PubMed  Google Scholar 

  77. George B, Mathews V, Viswabandya A et al (2010) Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia–a single-center analysis of 100 patients. Pediatr Hematol Oncol 27:122–131

    Article  CAS  PubMed  Google Scholar 

  78. Seth T, Kanga U, Sood P, Sharma V, Mishra P, Mahapatra M (2012) Audit of peripheral stem cell transplantation for aplastic anemia in multitransfused infected patients. Transpl Proc 44:922–924

    Article  CAS  Google Scholar 

  79. Mukhopadhyay A, Gupta P, Basak J et al (2012) Stem cell transplant: An experience from eastern India. Indian J Med Paediatr Oncol 33:203–209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Nair V, Sharma A, DAS S, Sharma S, Grover N, Kaur J (2013) Allogeneic haematopoietic stem cell transplantation: the Army hospital experience. Natl Med J India 26:6–11

    CAS  PubMed  Google Scholar 

  81. Shah CA, Karanwal A, Desai M, Pandya M, Shah R, Shah R (2015) Hematopoietic stem-cell transplantation in the developing world: experience from a center in Western India. J Oncol 710543. doi:https://doi.org/10.1155/2015/710543

  82. George B, Mahapatra M, Mishra P, Apte S, Damodar S, Khattry N et al (2015) Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience. Blood 126:4386–4386

    Article  Google Scholar 

  83. George B, Pn N, Devasia AJ et al (2018) Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biol Blood Marrow Transplant 24:494–500

    Article  CAS  PubMed  Google Scholar 

  84. Choudhury D, Kumar M, Sharma S, Khandelwal V, Doval D, Dadu D et al (2020) Real-world outcomes of stem cell transplantation for severe aplastic anemia: A single-center experience in Northern India. Blood Cell Therapy-The official journal of APBMT 3:32–36

    Google Scholar 

  85. Gupta N, Choudhary D, Sharma SK, Khandelwal V, Dhamija M (2015) Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY. Bone Marrow Transplant 50:155–156

    Article  CAS  PubMed  Google Scholar 

  86. Varma S, Varma N, Malhotra P, Singh S, Sharma DR (1999) Cyclosporine A monotherapy in young Indian aplastic anaemia patients. JIMA 97:292–293

    Google Scholar 

  87. Rai M, Singh VP, Shukla J, Sundar S, Jha VC (2001) Low dose cyclosporine-a therapy in severe aplastic anaemia. JAPI 49:966–969

    CAS  PubMed  Google Scholar 

  88. Shetty M, Narendra AM, Adiraju KP, Modugu NR (2016) Study of Aplastic Anaemia with Cyclosporine in Resource Poor Setting. J Clin Diagn Res 10:OC15–OC18

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Mandal PK, Baul S, Dolai TK, De R, Chakrabarti P (2017) Outcome of Cyclosporine Monotherapy in Patients of Aplastic Anemia: Experience of a Tertiary Care Hospital in Eastern India. Indian J Hematol Blood Transfus 33:144–147

    Article  PubMed  Google Scholar 

  90. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP (1985) Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 66:184–188

    Article  CAS  PubMed  Google Scholar 

  91. Bacigalupo A, Chaple M, Hows J et al (1993) Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol 83:145–115

    Article  CAS  PubMed  Google Scholar 

  92. Marwaha RK, Bansal D, Trehan A, Varma N (2004) Androgens in childhood acquired aplastic anaemia in Chandigarh, India. Trop Doct 34:149–152.

    Article  CAS  PubMed  Google Scholar 

  93. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207027s000lbl.pdf (Accessed on April 07, 2020)

  94. Scheinberg P (2018) Activity of eltrombopag in severe aplastic anemia. Blood Adv 2:3054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Fan X, Desmond R, Winkler T et al (2020) Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv 4:1700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. George B, Lionel S, Selvarajan S et al (2021) An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. Transplant Cell Ther:27(5):409.e1–409.e6

Download references

Acknowledgements

Nil.

Funding

Not Applicable.

Author information

Authors and Affiliations

  1. Department of Haematology, Nil Ratan Sircar Medical College and Hospital, Kolkata, India

    Tuphan Kanti Dolai

  2. Department of Medical oncology and Haematology, Medanta Medcity, India

    Manisha Jain

  3. Department of Haematology, All India Institute of Medical science, New Delhi, India

    Manoranjan Mahapatra

Authors
  1. Tuphan Kanti Dolai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manisha Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manoranjan Mahapatra
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr Tuphan Kanti Dolai- Concept, Literature search, write up, corrections.

Corresponding author

Correspondence to Tuphan Kanti Dolai.

Ethics declarations

Compliance with Ethical Standards

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolai, T.K., Jain, M. & Mahapatra, M. Idiopathic Aplastic anemia: Indian Perspective. Indian J Hematol Blood Transfus 39, 357–370 (2023). https://doi.org/10.1007/s12288-022-01592-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-022-01592-4

Keywords

Search

Navigation